Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD

ATOSSA THERAPEUTICS, INC.

Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.
Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy.
Added Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. as Medical Directors for breast oncology and rare diseases.
Interest income decreased to $2.4M from $4.1M; no impairment charge in 2025 vs $1.7M in 2024.
(Z)-endoxifen being evaluated in multiple settings including breast cancer and rare diseases DMD and MAS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 25, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the fourth quarter and year ended December 31, 2025 financial results and providing a Company update.

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-124393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.